Carpenter CC, Fischl MA, Hammer SM.
et al. Antiretroviral therapy for HIV infection in 1998. JAMA.1998;280:78-86.
Perelson AS, Essunger P, Cao Y.
et al. Decay characteristics of HIV-1-infected compartments during combination
Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Hammer SM, Squires KE, Hughes MD.
et al. A controlled trial of two nucleoside analogues plus indinavir in persons
with human immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. N Engl J Med.1997;337:725-733.
Palella FJJ, Delaney KM, Moorman AC.
et al. Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection. N Engl J Med.1998;338:853-860.
Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and
multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med.1998;128:906-911.
Patick AK, Duran M, Cao Y.
et al. Genotypic and phenotypic characterization of human immunodeficiency
virus type 1 variants isolated from patients treated with the protease inhibitor
nelfinavir. Antimicrob Agents Chemother.1998;42:2637-2644.
Eastman PS, Mittler J, Kelso R.
et al. Genotypic changes in human immunodeficiency virus type 1 associated
with loss of suppression of plasma viral RNA levels in subjects treated with
ritonavir (Norvir) monotherapy. J Virol.1998;72:5154-5164.
Molla A, Korneyeva M, Gao Q.
et al. Ordered accumulation of mutations in HIV protease confers resistance
to ritonavir. Nat Med.1996;2:760-766.
Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus. J Virol.1996;70:7894-7899.
Fatkenheuer G, Theisen A, Rockstroh J.
et al. Virological treatment failure of protease inhibitor therapy in an unselected
cohort of HIV-infected patients. AIDS.1997;11:F113-F116.
Duncombe C, Kaufmann G, Beveridge A.
et al. Durability of quadruple antiretroviral therapy including ritonavir
and saquinavir in patients with advanced HIV-1 disease. In: Program and abstracts of the Fifth Conference on Retroviruses
and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 390.
Deeks SG, Hecht FM, Swanson M.
et al. HIV-1 RNA and CD4 cell count response to protease inhibitor therapy
in an urban AIDS clinic: response to both initial and salvage therapy. AIDS.1999;13:F35-F43.
Sonnerburg A, Johansson B, Ayehunie S, Julander I. Transmission of zidovudine-resistant HIV-1. AIDS.1993;7:1684-1685.
Quigg M, Rebus S, France AJ, McMenamin J, Darby G, Leigh Brown AJ. Mutations associated with zidovudine resistance in HIV-1 among recent
Angarano G, Monno L, Appice A.
et al. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts. AIDS.1994;8:1013-1014.
Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants
associated with zidovudine resistance. J Infect Dis.1994;169:411-415.
Erice A, Mayers DL, Strike DG.
et al. Primary infection with zidovudine-resistant human immunodeficiency
virus type 1. N Engl J Med.1993;328:1163-1165.
Fitzgibbon JE, Gaur S, Frenkel LD, Laraque F, Edlin BR, Dubin DT. Transmission from one child to another of human immunodeficiency virus
type 1 with a zidovudine-resistance mutation. N Engl J Med.1993;329:1835-1841.
Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine
and zidovudine. J Infect Dis.1997;175:1502-1506.
Hecht FM, Grant RM, Petropoulos CJ.
et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase
and protease inhibitors. N Engl J Med.1998;339:307-311.
Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA.1998;279:1977-1983.
Cohen OJ, Fauci AS. Transmission of multidrug-resistant human immunodeficiency virus—the
wake-up call. N Engl J Med.1998;339:341-343.
Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Brown AJ. Human immunodeficiency virus-infected individuals contain provirus
in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol.1990;64:864-872.
Balfe P, Simmonds P, Ludlam CA, Bishop JO, Brown AJ. Concurrent evolution of human immunodeficiency virus type 1 in patients
infected from the same source. J Virol.1990;64:6221-6233.
Jena PK, Liu AH, Smith DS, Wysocki LJ. Amplification of genes, single transcripts and cDNA libraries from
one cell and direct sequence analysis of amplified products derived from one
molecule. J Immunol Methods.1996;190:199-213.
Felsenstein J. Phylogenies from molecular sequences. Annu Rev Genet.1988;22:521-565.
Kleim JP, Rosner M, Winkler I.
et al. Selective pressure of a quinoxaline nonnucleoside inhibitor of human
immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1
replication results in the emergence of nucleoside RT-inhibitor-specific (RT
Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci U S A.1996;93:34-38.
Tisdale M, Myers RE, Maschera B.
et al. Cross-resistance analysis of human immunodeficiency virus type 1 variants
individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother.1995;39:1704-1710.
Condra JH, Schleif WA, Blahy OM.
et al. In vivo emergence of HIV-1 variants resistant to multiple protease
Condra JH, Holder DJ, Schleif WA.
et al. Genetic correlates of in vivo viral resistance to indinavir, a human
immunodeficiency virus type 1 protease inhibitor. J Virol.1996;70:8270-8276.
Kozal MJ, Shah N, Shen N.
et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using
high-density oligonucleotide arrays. Nat Med.1996;2:753-759.
Hertogs K, de Bethune MP, Miller V.
et al. A rapid method for simultaneous detection of phenotypic resistance
to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency
virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother.1998;42:269-276.
Shi C, Mellors JW. A recombinant retroviral system for rapid in vivo analysis of human
immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother.1997;41:2781-2785.
Gervaix A, West D, Leoni LM, Richman DD, Wong-Staal F, Corbeil J. A new reporter cell line to monitor HIV infection and drug susceptibility
in vitro. Proc Natl Acad Sci U S A.1997;94:4653-4658.
Parkin N, Whitcomb J, Smith D.
et al. Use of a rapid phenotypic HIV-1 drug resistance and susceptibility
assay in analyzing the emergence of drug-resistant virus during triple combination
therapy. In: Program and abstracts of the 37th Interscience Conference on
Antimicrobial Agents and Chemotherapy; September 28–October 1, 1997;
Toronto, Ontario. Abstract LB-1.
Rosenberg ES, Billingsley JM, Caliendo AM.
et al. Vigorous HIV-1-specific CD4+ T-cell responses associated
with control of viremia. Science.1997;278:1447-1450.